Physician profile
Magdalena Dumin
NPI 1780983163
$15,247.46
in general payments reported to CMS, 2019-2025
8 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2021: $15.23 · 2022: $29.51 · 2023: $16.28 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,600 · Travel and Lodging: $852 · Food and Beverage: $460 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,925.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,600.00 |
| Travel and Lodging | $852.24 |
| Food and Beverage | $459.50 |
| Education | $117.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $11,511.21 | 2025 | |
| Abbvie INC. | $3,400.00 | 2025 | |
| Arbor Pharmaceuticals, INC. | $248.48 | 2019 | |
| Insulet Corporation | $26.75 | 2025 | Omnipod |
| Dexcom, INC. | $16.28 | 2023 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $16.17 | 2022 | |
| Abiomed | $15.23 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magdalena Dumin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.